Abstract
Patients with alveolar rhabdomyosarcoma (ARMS) have poorer response to conventional chemotherapy and lower survival rates than those with embryonal RMS (ERMS). By high-throughput screening, we identified camptothecin as an ARMS-selective inhibitor. Camptothecin more efficiently inhibited proliferation and induced apoptosis in Rh30 (ARMS) than RD (ERMS) cells. Ectopic expression of the PAX3-FKHR (PF) fusion protein in RD cells significantly increased sensitivity, whereas siRNA knockdown of PF decreased sensitivity of Rh30 cells to camptothecin. The sensitization required a transcriptionally active PF, and camptothecin downregulated levels of PF protein. These findings suggest that it is feasible to develop agents that preferentially block the growth of ARMS.
2009 Elsevier Ireland Ltd.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / pharmacology*
-
Apoptosis / drug effects
-
Camptothecin / pharmacology*
-
Cell Division / drug effects
-
Cell Line, Tumor / drug effects
-
Drug Resistance, Neoplasm / genetics
-
Forkhead Box Protein O1
-
Forkhead Transcription Factors / antagonists & inhibitors
-
Forkhead Transcription Factors / biosynthesis
-
Forkhead Transcription Factors / genetics
-
Forkhead Transcription Factors / physiology*
-
Gene Expression Regulation, Neoplastic / drug effects
-
Genes, Reporter
-
Humans
-
RNA Interference
-
RNA, Small Interfering / pharmacology
-
Rhabdomyosarcoma, Alveolar / drug therapy
-
Rhabdomyosarcoma, Alveolar / genetics
-
Rhabdomyosarcoma, Alveolar / metabolism*
-
Rhabdomyosarcoma, Alveolar / pathology
-
Transcription, Genetic
Substances
-
Antineoplastic Agents, Phytogenic
-
FOXO1 protein, human
-
Forkhead Box Protein O1
-
Forkhead Transcription Factors
-
RNA, Small Interfering
-
Camptothecin